Athira Pharma completes patient dosing in Phase 2/3 trial of fosgonimeton in AD

Athira Pharma, Inc. (NASDAQ: ATHA), a prominent biopharmaceutical company specializing in neurodegenerative diseases, has announced the completion of patient dosing in the Phase 2/3 LIFT-AD ... Read More